期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿卡波糖对糖耐量低减患者的心血管疾病的预防 被引量：2

The preventive effect of acarbose with imapired glucose tolerance population of cardiovascular disease
下载PDF
导出
摘要 目的评价阿卡波糖对糖耐量低减(IGT)患者的心血管疾病的预防作用。方法选择168例行口服葡萄糖耐量试验(OGTT)诊断为IGT的患者,随机分为两组,治疗组给予阿卡波糖,观察2年心血管事件的发生率。结果治疗组冠心病的发病率为9.30%,对照组冠心病的发病率为21.95%,两组比较,P<0.05差异有统计学意义。结论阿卡波糖对IGT患者能够显著降低心血管事件的发生。 Objective To investigate the preventive effect of acarbose with impaired glucose tolerance （IGT） population of developing coronary heart disease. Methods 168 patients with impaired glucose tolerance were randomly divided into control group and acarbose treatment group. All were observed carefully for two years to conclude the attack rate. Results The prevalence of coronary heart disease was 9, 30% in acarhose group, and was 21.95% in control group, （P 〈 0.05）. Conclusion The results showed that the attack rate from coronary heart disease in acarbose treatment group were less than those in the control group.
作者 彭庆奎
机构地区 山东省枣庄市立医院心内一科
出处 《中国实用医药》 2008年第13期51-52,共2页 China Practical Medicine
关键词 糖耐量低减 冠心病 阿卡波糖 发病率 IGT Coronary heart disease Acarbose Attack rate
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献7

  • 1[1]The expert committee on the diagnosis and classification of diabetes mellitus:follow-up report on the diagnosis of diabetes mellitns.Diabetes Care,2003,26(11):3160-3167.
  • 2[2]Meigs JB,Nathan DM,D'Agostino RB Sr,et al.Fasting and postchallenge glycemia and cardiovascular disease risk:the Framingham offspring study.Diabetes Care,2002,25 (7):1845-1850.
  • 3[3]Knowler WC,Barrett Connor E,Fowler SE,et al.Reduction in the incidence of type 2 diabetes with lifestyle intervention or mefformin.N Engl J Med,2002,346 (6):393 -403.
  • 4[4]Hanefeld M,Koehler C,Henkel E,et al.Post-challenge hyperglycemia relates more strongly than fasting hyperglycemia with carotid intimanmedia thickness:the RIAD study.Diabct Med,2000,17 (12):212-218.
  • 5[5]DECOOE Study Group.The European Diabetes Epidemiology Group.Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria.Arch Intern Med,2001,161 (3):397-405.
  • 6[6]Broenlee M.The pathobiology of diabetic complication:a unifying mechanism.Diabetes,2004,53 (12):6.
  • 7赵铁耘,李秀钧.糖尿病诊治研究新理念[J].中国实用内科杂志,2005,25(4):302-304. 被引量：46

二级参考文献9

  • 1李军,李秀钧,张杰,罗梅,周桥,赵桂芝.糖耐量受损大鼠胰岛α细胞胰高血糖素及神经肽Y的表达[J].中华内分泌代谢杂志,2004,20(3):185-189. 被引量：31
  • 2Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.N Engl J Med,2002,346(6) :393-403.
  • 3Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA,2003,290(4) :486-494.
  • 4Hanefeld M, Koehler C, Henkel E, et al. Post-challenge hyperglycemia relates more strongly than fasting hyperglycemia with carotid intimae-media thickness: the RIAD study. Diabet Med, 2000, 17(12) :212-218.
  • 5DECOOE Study Group. The European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality:comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med,2001,161( 3 ) :397-405.
  • 6Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose tolerant individuals with a first-degree NIDDM relative. JAMA, 1995,273 (23): 1855-1861.
  • 7Luo M, Xiujun L, Li J, et al. Study on insulin receptor content and distribution of islet α-cell in diabetic rats-prelimary insight into the mechanism of pancreasticd-cell insulin resistance. Diabetes, 2004,53 (suppl 2) :A313.
  • 8Broenlee M. The pathobiology of diabetic complication:a unifying mechanism. Diabetes,2004,53 (suppl 2) :6.
  • 9The expert committee on the diagnosis and classification of diabetes mellitus:follow-up report on the diagnosis of diabetes mellitus. Diabetes Care,2003,26( 11 ) :3160-3167.

共引文献45

同被引文献54

  • 1赵铁耘,李秀钧.糖尿病诊治研究新理念[J].中国实用内科杂志,2005,25(4):302-304. 被引量：46
  • 2COLWELL J A, NESTOR W. The platelet in diabe- tes: focus on prevention of ischemic events[J]. Diabe- tes Care,2003,26:2181-- 2188.
  • 3MELCHIOR T, RASK M C, TORP P C, et al. The impact of heart failure on prognosis of diabetic and nondi- abetic patients with myocardial infarction., a 15-yearfol- low-up study[J]. Eur J Heart Fail, 2001,3 : 83 -- 90.
  • 4LEDRU F, DUCIMETIERE P, BATTAGLIA S, et al. New diagonstic criteria for diabetes and coronary artery disease: insights from an angiographic study [J]. J Am Coil Cardiol,2001,37:1543--1550.
  • 5CHIASSON J L, JOSSE R G, GOMIS R, et al. Acarbose treatment and the risk of cardiovascular disease and hyper- tension in patients with impaired glucose tolerance: the STOP-NIDDM trial[J]. JAMA, 2003,290: 486-- 494.
  • 6BROENLEE M. The pathohiology of diabetic compli- cation: a unifying mechanism [J ]. Diabetes, 2005,54 : 1615--1625.
  • 7STEFAN N, STUMVOLL M, VOZAROVA B, et al. Plasma adiponectin and endogenous glucose production in humans[J]. Diabetes Care, 2003,26 :3315 -- 3319.
  • 8HENNIG B, MEERARANI P, RAMADASS P, et al. Fatty acid-mediated activation of vascular endothelial cells[J].Metabolism, 2000,49 : 1006 -- 1013.
  • 9HURLEY L, PRINS J B. Fat as endocrine organ:re- lationship to the metabolic synd-rome[J]. Am J Med Sci, 2005,330 : 280-- 289.
  • 10DIEZ J J, IGESIAS P. The role of the novel adipo- cyte-derived hormone adiponectin in humandisease [J]. Eur J Endocrinol, 2003,148 : 293-- 300.

引证文献2

二级引证文献23

中国实用医药
2008年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部